BACKGROUND AND PURPOSE: Although NAA is often used as a marker of neural integrity and health in different neurologic disorders, the temporal behavior of WBNAA is not well characterized. Our goal therefore was to establish its normal variations in a cohort of healthy adults over typical clinical trial periods. MATERIALS AND METHODS: Baseline amount of brain NAA, Q(NAA), was obtained with nonlocalizing proton MR spectroscopy from 9 subjects (7 women, 2 men; 31.2 ± 5.6 years old). Q(NAA) was converted into absolute millimole amount by using phantom-replacement. The WBNAA concentration was derived by dividing Q(NAA) with the brain parenchyma volume, V(B), segmented from MR imaging. Temporal variations were determined with 4 annual scans of each participant. RESULTS: The distribution of WBNAA levels was not different among time points with respect to the mean, 12.1 ± 1.5 mmol/L (P > .6), nor was its intrasubject change (coefficient of variation = 8.6%) significant between any 2 scans (P > .5). There was a small (0.2 mL) but significant (P = .05) annual V(B) decline. CONCLUSIONS: WBNAA is stable over a 3-year period in healthy adults. It qualifies therefore as a biomarker for global neuronal loss and dysfunction in diffuse neurologic disorders that may be well worth considering as a secondary outcome measure candidate for clinical trials.
BACKGROUND AND PURPOSE: Although NAA is often used as a marker of neural integrity and health in different neurologic disorders, the temporal behavior of WBNAA is not well characterized. Our goal therefore was to establish its normal variations in a cohort of healthy adults over typical clinical trial periods. MATERIALS AND METHODS: Baseline amount of brain NAA, Q(NAA), was obtained with nonlocalizing proton MR spectroscopy from 9 subjects (7 women, 2 men; 31.2 ± 5.6 years old). Q(NAA) was converted into absolute millimole amount by using phantom-replacement. The WBNAA concentration was derived by dividing Q(NAA) with the brain parenchyma volume, V(B), segmented from MR imaging. Temporal variations were determined with 4 annual scans of each participant. RESULTS: The distribution of WBNAA levels was not different among time points with respect to the mean, 12.1 ± 1.5 mmol/L (P > .6), nor was its intrasubject change (coefficient of variation = 8.6%) significant between any 2 scans (P > .5). There was a small (0.2 mL) but significant (P = .05) annual V(B) decline. CONCLUSIONS: WBNAA is stable over a 3-year period in healthy adults. It qualifies therefore as a biomarker for global neuronal loss and dysfunction in diffuse neurologic disorders that may be well worth considering as a secondary outcome measure candidate for clinical trials.
Authors: C E Coffey; W E Wilkinson; I A Parashos; S A Soady; R J Sullivan; L J Patterson; G S Figiel; M C Webb; C E Spritzer; W T Djang Journal: Neurology Date: 1992-03 Impact factor: 9.910
Authors: Andrew R Tsen; Patrick M Long; Heather E Driscoll; Matthew T Davies; Benjamin A Teasdale; Paul L Penar; William W Pendlebury; Jeffrey L Spees; Sean E Lawler; Mariano S Viapiano; Diane M Jaworski Journal: Int J Cancer Date: 2013-09-30 Impact factor: 7.396
Authors: M Wagner; A Jurcoane; C Hildebrand; E Güresir; H Vatter; F E Zanella; J Berkefeld; U Pilatus; E Hattingen Journal: AJNR Am J Neuroradiol Date: 2013-02-22 Impact factor: 3.825
Authors: D J Rigotti; M Inglese; I I Kirov; E Gorynski; N N Perry; J S Babb; J Herbert; R I Grossman; O Gonen Journal: Neurology Date: 2012-04-18 Impact factor: 9.910
Authors: Patrick M Long; Scott W Tighe; Heather E Driscoll; Karen A Fortner; Mariano S Viapiano; Diane M Jaworski Journal: J Cell Physiol Date: 2015-08 Impact factor: 6.384
Authors: Brian J Soher; William E Wu; Assaf Tal; Pippa Storey; Ke Zhang; James S Babb; Ivan I Kirov; Yvonne W Lui; Oded Gonen Journal: NMR Biomed Date: 2014-09-05 Impact factor: 4.044
Authors: Johan Mellergård; Anders Tisell; Olof Dahlqvist Leinhard; Ida Blystad; Anne-Marie Landtblom; Kaj Blennow; Bob Olsson; Charlotte Dahle; Jan Ernerudh; Peter Lundberg; Magnus Vrethem Journal: PLoS One Date: 2012-09-17 Impact factor: 3.240
Authors: Abhilash P Appu; John R Moffett; Peethambaran Arun; Sean Moran; Vikram Nambiar; Jishnu K S Krishnan; Narayanan Puthillathu; Aryan M A Namboodiri Journal: Front Mol Neurosci Date: 2017-06-02 Impact factor: 5.639
Authors: Patrick M Long; Scott W Tighe; Heather E Driscoll; John R Moffett; Aryan M A Namboodiri; Mariano S Viapiano; Sean E Lawler; Diane M Jaworski Journal: PLoS One Date: 2013-11-20 Impact factor: 3.240